KRRO
Korro Bio, Inc. (NASDAQ)
Healthcare — Biotechnology
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Price History
Fundamentals
| Market Cap | $196.87M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.71 |
| EPS (TTM) | $-11.68 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -87.78% |
| Debt/Equity | 35.85 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $20.00 |
| Analysts | 10 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 67.4 |
| Beta | 2.10 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $55.89 |
| 52-Week Low | $5.20 |
| 50-Day Avg | $12.14 |
| 200-Day Avg | $16.96 |
| Avg Volume | 189.9K |
| Volume | 73.5K |
Performance Analysis
BULLISHKRRO shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:17 UTC
Back to Screener Export Report